291 related articles for article (PubMed ID: 32963023)
1. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.
Evans WK; Gauvreau CL; Flanagan WM; Memon S; Yong JHE; Goffin JR; Fitzgerald NR; Wolfson M; Miller AB
CMAJ Open; 2020; 8(3):E585-E592. PubMed ID: 32963023
[TBL] [Abstract][Full Text] [Related]
2. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
Mahadevia PJ; Fleisher LA; Frick KD; Eng J; Goodman SN; Powe NR
JAMA; 2003 Jan; 289(3):313-22. PubMed ID: 12525232
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of computed tomography screening for lung cancer in the United States.
McMahon PM; Kong CY; Bouzan C; Weinstein MC; Cipriano LE; Tramontano AC; Johnson BE; Weeks JC; Gazelle GS
J Thorac Oncol; 2011 Nov; 6(11):1841-8. PubMed ID: 21892105
[TBL] [Abstract][Full Text] [Related]
5. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions.
Villanti AC; Jiang Y; Abrams DB; Pyenson BS
PLoS One; 2013; 8(8):e71379. PubMed ID: 23940744
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of a Telephone-Based Smoking Cessation Randomized Trial in the Lung Cancer Screening Setting.
Cao P; Smith L; Mandelblatt JS; Jeon J; Taylor KL; Zhao A; Levy DT; Williams RM; Meza R; Jayasekera J
JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35818125
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
Hoogendoorn M; Welsing P; Rutten-van Mölken MP
Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Enhanced vs Standard Varenicline Treatment for Tobacco Cessation.
Mundt MP; Stein JH; Fiore MC; Baker TB
JAMA Netw Open; 2024 Apr; 7(4):e248727. PubMed ID: 38683609
[TBL] [Abstract][Full Text] [Related]
9. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
von Wartburg M; Raymond V; Paradis PE
Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and health impact of lung cancer screening with low-dose computed tomography for never smokers in Japan and the United States: a modelling study.
Kowada A
BMC Pulm Med; 2022 Jan; 22(1):19. PubMed ID: 34996423
[TBL] [Abstract][Full Text] [Related]
11. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.
Wang D; Connock M; Barton P; Fry-Smith A; Aveyard P; Moore D
Health Technol Assess; 2008 Feb; 12(2):iii-iv, ix-xi, 1-135. PubMed ID: 18093448
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
[TBL] [Abstract][Full Text] [Related]
15. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
Bolin K; Lindgren B; Willers S
Chest; 2006 Mar; 129(3):651-60. PubMed ID: 16537864
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of extended cessation treatment for older smokers.
Barnett PG; Wong W; Jeffers A; Munoz R; Humfleet G; Hall S
Addiction; 2014 Feb; 109(2):314-22. PubMed ID: 24329972
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research.
Cromwell J; Bartosch WJ; Fiore MC; Hasselblad V; Baker T
JAMA; 1997 Dec; 278(21):1759-66. PubMed ID: 9388153
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
Lutz MA; Lovato P; Cuesta G
Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
[TBL] [Abstract][Full Text] [Related]
19. Potential Impact of Cessation Interventions at the Point of Lung Cancer Screening on Lung Cancer and Overall Mortality in the United States.
Cao P; Jeon J; Levy DT; Jayasekera JC; Cadham CJ; Mandelblatt JS; Taylor KL; Meza R
J Thorac Oncol; 2020 Jul; 15(7):1160-1169. PubMed ID: 32160967
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan.
Igarashi A; Takuma H; Fukuda T; Tsutani K
Pharmacoeconomics; 2009; 27(3):247-61. PubMed ID: 19354344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
